Why the best CROs challenge the trial plan and keep challeng...
Too often, oncology trials fail for reasons that could have been anticipated and addressed.
Newsletters and Deep Dive digital magazine
Too often, oncology trials fail for reasons that could have been anticipated and addressed.
As AI adoption increases, it is exposing just how prepared organisations really are to operate in a digitally connected environment.
Report turnaround time has become a key metric for diagnostic centres, shaping much of the automation built around their work.
Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test
As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia
Editor's Picks
Newsletters and Deep Dive
digital magazine